Gut microbiota-derived metabolites are increasingly recognized as key mediators of interorgan communication in cardiovascular disease. However, the field has often relied on a single-metabolite hypothesis, particularly centered on trimethylamine N-oxide (TMAO), which does not fully capture the complexity of host-microbe-organ interactions. In this review, we argue that cardiovascular risk is better understood as a network of interacting gut-derived molecules, in which TMAO functions as a node within a broader system that includes phenylacetylglutamine, indole-related metabolites, short-chain fatty acids, bile acids, and lipopolysaccharide. Within this framework, the TMAO two-hit model, in which pre-existing organ vulnerability (first hit) is exacerbated by metabolite elevations (second hit), exemplifies context-dependent pathogenicity, particularly in chronic kidney disease or other pre-existing cardiometabolic vulnerabilities. We further discuss how this network-based view may refine biomarker interpretation, improve patient stratification, and guide the development of biomarker-guided strategies for microbiome-targeted interventions. By reframing gut-derived metabolites as part of an interorgan communication network rather than isolated mediators, this review aims to provide a more integrated translational perspective for cardiovascular pathophysiology and patient stratification.
No takes yet. Share an insight, caveat, or question.
Chong et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: